2VJ Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.09 |
52 Week High | HK$0.26 |
52 Week Low | HK$0.086 |
Beta | 0.64 |
11 Month Change | -25.62% |
3 Month Change | -41.94% |
1 Year Change | -60.18% |
33 Year Change | -75.41% |
5 Year Change | -86.15% |
Change since IPO | -92.17% |
Recent News & Updates
Recent updates
Shareholder Returns
2VJ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -5.8% | -0.5% | 0.8% |
1Y | -60.2% | -18.9% | 2.0% |
Return vs Industry: 2VJ underperformed the German Biotechs industry which returned -18.9% over the past year.
Return vs Market: 2VJ underperformed the German Market which returned 2% over the past year.
Price Volatility
2VJ volatility | |
---|---|
2VJ Average Weekly Movement | 14.8% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2VJ's share price has been volatile over the past 3 months.
Volatility Over Time: 2VJ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
2VJ fundamental statistics | |
---|---|
Market cap | €96.85m |
Earnings (TTM) | -€18.59m |
Revenue (TTM) | €7.27m |
13.3x
P/S Ratio-5.2x
P/E RatioIs 2VJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2VJ income statement (TTM) | |
---|---|
Revenue | CN¥56.60m |
Cost of Revenue | CN¥30.61m |
Gross Profit | CN¥25.99m |
Other Expenses | CN¥170.71m |
Earnings | -CN¥144.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.14 |
Gross Margin | 45.92% |
Net Profit Margin | -255.70% |
Debt/Equity Ratio | 0% |
How did 2VJ perform over the long term?
See historical performance and comparison